In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations

Ibrexafungerp is a first-in-class glucan synthase inhibitor. In vitro activity was determined for 89 Candida glabrata isolates with molecularly identified FKS1 or FKS2 mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Autores principales: Nunnally, Natalie S., Etienne, Kizee A., Angulo, David, Lockhart, Shawn R., Berkow, Elizabeth L.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2019
Materias:
Susceptibility
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6811432/
https://ncbi.nlm.nih.gov/pubmed/31481447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01692-19
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares